Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
-13M
-
Total reported value, excl. options
-
$90.5M
-
Value change
-
-$232M
-
Number of buys
-
18
-
Number of sells
-
-27
-
Price
-
$6.30
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q4 2018
53 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2018.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 120M outstanding shares and own 11.96% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (11.5M shares), ALLIANCEBERNSTEIN L.P. (651K shares), BlackRock Inc. (642K shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (474K shares), Vanguard Group Inc (339K shares), WASATCH ADVISORS INC (145K shares), BANK OF MONTREAL /CAN/ (120K shares), BAKER BROS. ADVISORS LP (99.6K shares), NORTHERN TRUST CORP (58.1K shares), and GEODE CAPITAL MANAGEMENT, LLC (44.2K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.